L'ESTRACYT NEL CARCINOMA PROSTATICO AVANZATO: Considerazioni e riflessioni

Andersson L. , Edsmyr F. , Jonsson G. , Konyves L. : Estracyt therapy in carcinoma of the prostate. Cancer Res., 60; 73–74 (1977).

Brukowsky N. , Lesser B. , Van Doom E. , Cravens : Hormonal effects on cell proliferation in rat prostate. Vit. & Horm., 33; 61 (1975).

Dixon R. , Brooks M. , Gill G. : Estramustine phosphate: plasma concentrations of its metabolites following oral administration to man, rat and dog. Res. Comm. Chem. Pathol. Pharmacol., 27; 17–29 (1980).

Forshellg P. , Muntzing J. , Ek A. : The absorbtion, metabolism and escretion of Estracyt in patients with prostatic cancer. Invest. Urol., 14; 128–131 (1976).

Fossa S. , Fossa J. , Aakvaag A. : Hormone changes in patients with prostatic carcinoma during treatment with Estramustine phosphate. J. Urol., 118; 1013–1018 (1977).

Fritjoffson A. , Cekan Z. , Diczafalusy E. : Hormonal effects of different doses of Estramustine phosphate (Estracyt) in patients with prostatic cancer. J. Urol., 15; 37–44 (1981).

Hogberg B. : Estramustine binding protein (E.M.B.P.). Acta Urol. Belg., 48; 123 (1980).

Hoisaeter A. : Incorporation of 3H-thymidine into rat ventral prostate in organ culture. Influence of hormone-cytostatic complexes. Invest. Urol., 12; 479 (1975).

Hoisaeter A. : Effect of steroidal alkylating agent (Estramustine phosphate) in rat ventral prostate. Scand. J. Urol. & Nephrol., Suppl. 46; 1–72 (1977).

Kalland , Haukaas S. : Effect of treatment with diethil-stiblestrol-pliestradiol phosphate or estramustine phosphate (Estracyt) on natural killer cell activity in patients with prostatic cancer. Invest. Urol., 18; 437–439 (1981).

Karr J. P. , Wassman Z. , Kirdani R. Y. : Effects of DES and E. on sex hormone binding globuline and T levels in prostatic cancer patients. J. Urol., 142; 232–236 (1980).

Kadohama N. , Kirdani R. Y. , Madajewiz S. , Murphy G. P. , Sandberg A. A. : Estramustine. Metabolic pattern and possible mechanism for its action in prostate cancer. N. Y. State J. Med., 79; 1005–1009 (1979).

Leistenschneider , Nagel R. : Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytologic and DNA cytophotometry. Eur. Urol., 6; 111–115 (1980).

Muntzing J. , Kirdani R. J. , Sarof J. , Purphy G. P. , Sandberg A. A. : Inhibitory effect of R-3327 rat prostatic carcinoma. Urology, 10; 439–445 (1974).

Muntzing J. , Shukla S. K. , Chu T. M. , Mittelman A. , Purphy G. P. : Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate. Invest. Urol., 12; 65 (1974).

Murphy G. P. : In: Skinner, De Kernion: Genitourinary cancer, pag. 409. Saunders, Philadelphia 1978.

Nilsson T. : Clinical experience with Estracyt. Acta Urol. Belg., 48; 133–137 (1980).

Pannuti Periti : Comunicazione personale al « Simposio Nazionale sul Medrossiprogesterone Acetato », Firenze 1981.

Sandberg A. A. : Rationale and practice of testing chemiotherapeutic agents for prostatic cancer. Urology, 17; Suppl. al n. 4, p. 37–38 (1981).

Tritsch G. , Shukla S. , Mittelman A. , Purphy G. P. : Estracyt as a substrate for phosphatases in human serum. Invest. Urol., 12; 38–39 (1974).

Vanregemorter G. , Germeau F. : Estracyt and radiotherapy on the treatment of prostatic carcinoma. Acta Urol. Belg., 48; 138–148 (1980).